hal Application No PCT/EP2004/053497

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/439 C07 C07D498/08 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category 1 Relevant to claim No. P.Y WO 2004/105765 A (JANSSEN PHARMACEUTICA 1-12 N.V; FREYNE, EDDY, JEAN, EDGARD; PERERA, TIMOTHY) 9 December 2004 (2004-12-09) claims 1,9,11 Υ WO 03/082290 A (BOEHRINGER INGELHEIM 1-12 PHARMA GMBH & CO. KG; HIMMELSBACH, FRANK; JUNG, B) 9 October 2003 (2003-10-09) claims 1,9 WO 98/43960 A (AMERICAN CYANAMID COMPANY) 1-12 8 October 1998 (1998-10-08) claims 1,21 -/---Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-'O' document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled *P* document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 30 March 2005 12/04/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Bérillon, L

Internation No
PCT/EP2004/053497

		PCT/EP2004/053497
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PALMER B D ET AL: "Tyrosine Kinase Inhibitors. 11. Soluble Analogs of Pyrrolo— and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 10, 1997, pages 1519–1529, XP002094613 ISSN: 0022-2623 the whole document	1-12
A	HENNEQUIN L F ET AL: "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, no. 6, 14 March 2002 (2002-03-14), pages 1300-1312, XP002256124 ISSN: 0022-2623 the whole document	1-12



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)							
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:							
1. X Claims Nos.: 10 because they relate to subject matter not required to be searched by this Authority, namely:							
Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.							
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:							
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).							
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)							
This international Searching Authority found multiple inventions in this international application, as follows:							
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.							
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.							
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:							
octors any management that party opening that the same reads							
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:							
Remark on Protest The additional search fees were accompanied by the applicant's protest.							
No protest accompanied the payment of additional search fees.							

Information on patent family members

Intermedial Application No PCT/EP2004/053497

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 2004105765	Α	09-12-2004	WO	2004105765 A1	09-12-2004
WO 03082290	A	09-10-2003	DE DE AU BR CA WO EP US	10214412 A1 10231711 A1 2003226705 A1 0308902 A 2476008 A1 03082290 A1 1492536 A1 2004048880 A1	09-10-2003 22-01-2004 13-10-2003 04-01-2005 09-10-2003 09-10-2003 05-01-2005 11-03-2004
WO 9843960	A	08-10-1998	ATU AU BRA CN DE DE ES HU NO PT RS RN VA	250583 T 750906 B2 6877798 A 9808478 A 2285241 A1 1121391 C 69818442 D1 69818442 T2 973746 T3 0973746 A1 2209124 T3 1024917 A1 0002112 A2 2001519788 T 994798 A 337782 A 335999 A1 973746 T 2202551 C2 135799 A3 9902946 T2 9843960 A1 9802771 A	15-10-2003 01-08-2002 22-10-1998 30-09-2003 08-10-1998 17-09-2003 30-10-2003 08-07-2004 02-02-2004 26-01-2000 16-06-2004 02-01-2004 28-09-2000 23-10-2001 24-11-1999 27-04-2001 05-06-2000 27-02-2004 20-04-2003 16-05-2000 08-10-1998 01-10-1999